Advertisement

Drug Safety

, Volume 27, Issue 11, pp 773–797 | Cite as

Drug Interactions with St John’s Wort

Mechanisms and Clinical Implications
  • Marcus Mannel
Review Article

Abstract

The purpose of this paper is to review preclinical and clinical evidence relating to drug interactions with preparations of the medicinal herb St John’s wort (Hypericum perforatum). A systematic literature search was carried out in three electronic databases up to June 2004. Information about case reports classified as St John’s wort drug interactions was retrieved from the WHO Collaborating Centre for International Drug Monitoring and from the UK Medicines and Healthcare products Regulatory Agency in June 2003.

Against the background of proven efficacy in mild to moderate depressive disorders and an excellent tolerability profile in monotherapy, there is sufficient evidence from interaction studies and case reports to suggest that St John’s wort may induce the cytochrome P450 (CYP) 3A4 enzyme system and the P-glycoprotein drug transporter in a clinically relevant manner, thereby reducing efficacy of co-medications. Drugs most prominently affected and contraindicated for concomitant use with St John’s wort are metabolised via both CYP3A4 and P-glycoprotein pathways, including HIV protease inhibitors, HIV non-nucleoside reverse transcriptase inhibitors (only CYP3A4), the immunosuppressants ciclosporin and tacrolimus, and the antineoplastic agents irinotecan and imatinib mesylate. Efficacy of hormonal contraceptives may be impaired as reflected by case reports of irregular bleedings and unwanted pregnancies. Drugs with a narrow therapeutic index should be monitored more closely when St John’s wort is added, discontinued or the dosage is changed. The St John’s wort constituent hyperforin is probably responsible for CYP3A4 induction via activation of a nuclear steroid/pregnane and xenobiotic receptor (SXR/PXR) and hypericin may be assumed to be the P-glycoprotein inducing compound, although the available evidence is less convincing.

Combinations of St John’s wort with serotonergic agents and other antidepressants should be restricted to prescription-only, by experienced clinicians, due to potential central pharmacodynamic interactions.

In conclusion, providing certain precautions and contraindications are followed, and adequate information is given to healthcare professionals and patients, the safe and effective use of quality-tested St John’s wort products can be ensured.

Keywords

Hypericin Fexofenadine Hyperforin Talinolol International Drug Monitoring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The author thanks Rudolf Stoller of Swissmedic, Bern, Switzerland, and Leigh Henderson of the Medicines and Healthcare products Regulatory Agency, London, UK, for the provision of case report data and for discussing the drug regulatory agencies’ view of the topic. Andreas Johne of the Institute of Clinical Pharmacology, Charité, Humboldt-University Berlin, Germany, and Harald Murck of Laxdale Ltd, Sterling, UK, reviewed the manuscript thoroughly and gave valuable hints for interpretation and discussion of the data. Richard W. Middleton of Medicherb UK Ltd, Marlow, UK, was a great help in proofreading and improving the linguistic quality of the manuscript and further made useful comments and suggestions for discussion of the topic.

Potential conflicts of interest/funding: from 1997–2001 the author was on the permanent staff of Lichtwer Pharma, Germany, a pharmaceutical company manufacturing St John’s wort products. The author is occasionally paid by Lichtwer Pharma for medical consulting services in the field of phytotherapy.

Lichtwer Pharma supported this work by granting the author free access to literature database accounts.

References

  1. 1.
    Roth L. Hypericum, Hypericin. Botanik, Inhaltsstoffe, Wirkung. Landsberg: Ecomed, 1990: 125–9Google Scholar
  2. 2.
    Barnes J, Anderson LA, Phillipson JD. St John’s wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001 May; 53(5): 583–600PubMedCrossRefGoogle Scholar
  3. 3.
    Bilia AR, Gallori S, Vincieri FF. St John’s wort and depression: efficacy, safety and tolerability: an update. Life Sci 2002 May 17; 70(26): 3077–96PubMedCrossRefGoogle Scholar
  4. 4.
    Kim HL, Streltzer J, Goebert D. St John’s wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999; 187: 532–9PubMedCrossRefGoogle Scholar
  5. 5.
    Linde K, Mulrow CD. St John’s wort for depression (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 5. Oxford: Update Software, 2001Google Scholar
  6. 6.
    Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001; 16: 239–52PubMedCrossRefGoogle Scholar
  7. 7.
    Williams Jr JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743–56743-56PubMedGoogle Scholar
  8. 8.
    Arzneimittelkommission der Deutschen Arzteschaft (ed). Empfehlungen zur Therapie der Depression [Drug Commission of the German Medical Association (ed.). Recommendations for the treatment of depression]. In: Arzneiverordnung in der Praxis, Sonderheft 8. Koln: Arzneimittelkommission der Deutschen Arzteschaft, 1997Google Scholar
  9. 9.
    Volz HP, Murck H, Kasper S, et al. St John’s wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology 2002; 164: 294–300PubMedCrossRefGoogle Scholar
  10. 10.
    Müller T, Mannel M, Murck H, et al. Treatment of somatoform disorders with St John’s wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 2004; 66(4): 538–47PubMedCrossRefGoogle Scholar
  11. 11.
    Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. Br J Obstet Gynaecol 2000; 107: 870–6CrossRefGoogle Scholar
  12. 12.
    Taylor LH, Kobak KA. An open-label trial of St John’s wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000; 61: 575–8PubMedCrossRefGoogle Scholar
  13. 13.
    Friede M, Wustenberg P. Johanniskraut zur Therapie von Angstsyndromen bei depressiven Verstimmungen. Z Phytother 1998; 19: 309–17Google Scholar
  14. 14.
    Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients: a meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology 2002; 164: 301–8PubMedCrossRefGoogle Scholar
  15. 15.
    Davidson JR, Connor KM. St John’s wort in generalized anxiety disorder: three case reports. J Clin Psychopharmacol 2001; 21: 635–6PubMedCrossRefGoogle Scholar
  16. 16.
    Winkel R, Koritsch HD, Piayda H, et al. St John’s wort extract LI 160 in depressive, alcohol-addicted patients [abstract]. Phytomedicine 2000; 7Suppl. 2: 19Google Scholar
  17. 17.
    Hubner WD, Kirste T. Experience with St John’s wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res 2001; 15: 367–70367-70PubMedCrossRefGoogle Scholar
  18. 18.
    Greeson JM, Sanford B, Monti DA. St John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 2001 Feb; 153(4): 402–14CrossRefGoogle Scholar
  19. 19.
    Muller WE. Current St John’s wort research from mode of action to clinical efficacy. Pharmacol Res 2003 Feb; 47(2): 101–9PubMedCrossRefGoogle Scholar
  20. 20.
    Czekalla J, Gastpar M, Hubner WD, et al. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 1997; 30Suppl. 2: 86–8PubMedCrossRefGoogle Scholar
  21. 21.
    Dimpfel W, Todorova A, Vonderheid-Guth B. Pharmacodynamic properties of St John’s wort: a single-blind neurophysiological study in healthy subjects comparing two commercial preparations. Eur J Med Res 1999; 4: 303–12PubMedGoogle Scholar
  22. 22.
    Schmidt U, Sommer H. Johanniskraut-Extrakt zur ambulanten Therapie der Depression. Fortschr Med 1993; 111: 339–42PubMedGoogle Scholar
  23. 23.
    Ernst E, Rand JI, Barnes J, et al. Adverse effect profile of the herbal antidepressant St John’s wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54: 589–94PubMedCrossRefGoogle Scholar
  24. 24.
    Stevinson C, Ernst E. Safety of hypericum in patients with depression: a comparison with conventional antidepressants. CNS Drugs 1999 Feb; 11(2): 125–32CrossRefGoogle Scholar
  25. 25.
    Hubner WD, Arnoldt KH. St John’s wort: a one year treatment study [in German]. Z Phytother 2000; 21: 306–10Google Scholar
  26. 26.
    Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001 Mar; 8(2): 152–60PubMedGoogle Scholar
  27. 27.
    Kerb R, Bauer S, Brockmoeller J, et al. Urinary 6-p-hydroxycortisol excretion rate is affected by treatment with hypericum extract [abstract]. Eur J Clin Pharmacol 1997; 52Suppl.: A186Google Scholar
  28. 28.
    Ernst E. Second thoughts about safety of St John’s wort [published erratum appears in Lancet 2000 Feb 12; 355 (9203): 580]. Lancet 1999 Dec 11; 354(9195): 2014–6PubMedCrossRefGoogle Scholar
  29. 29.
    Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000 Feb 12; 355(9203): 548–9PubMedCrossRefGoogle Scholar
  30. 30.
    Federal Institute for Drugs and Medical Devices. Announcement regarding drug authorisation and registration -clearance of drug-related safety risks, hearing, stage II. Human medicinal drugs containing Hypericum (St John’s wort) for oral application [in German]. BAnz 2000 Apr 4; 66Google Scholar
  31. 31.
    Public statement on the risk of drug interactions with Hypericum perforatum (St John’s wort) and antiretroviral medicinal products. London: European Medicines Evaluation Agency, 28 Feb 2000 [online]. Available from URL: http://www.eudra.org/emea.html [Accessed 2003 Jul 31]
  32. 32.
    St John’s wort may influence other medication. Uppsala: Medical Products Agency, 2002 Feb 6 [online]. Available from URL: http://www.mpa.se [Accessed 2003 Jul 31]
  33. 33.
    Breckenridge A. Important interactions between St John’s wort (Hypericum perforatum) preparations and prescribed medicines. London: Medicines Control Agency -Committee on Safety of Medicines, 2000 Feb 29 [online]. Available from URL: http://www.mca.gov.uk [Accessed 2003 Jul 31]Google Scholar
  34. 34.
    Lumpkin MM, Alpert S. FDA public health advisory: risk of drug interactions with St John’s wort and indinavir and other drugs. US Food and Drug Administration -Center for Drug Evaluation and Research, 2000 Feb 10 [online]. Available from URL: http://www.fda.gov [Accessed 2003 Jul 31]Google Scholar
  35. 35.
    Mehta U. Potentially serious drug interactions between St John’s Wort and other medicines [letter]. S Afr Med J 2000 Jul; 90(7): 698PubMedGoogle Scholar
  36. 36.
    Potential drug interactions with St John’s wort. Health Canada, 2000 Apr 7 [online]. Available from URL: http://www.hcsc.gc.ca/english/index.html [Accessed 2003 Jul 31]
  37. 37.
    Bon S, Hartmann K, Kuhn M. Johanniskraut: Ein Enzyminduktor? Schweizer Apothekerzeitung 1999; 16: 535–6Google Scholar
  38. 38.
    Henderson L, Yue QY, Bergquist C, et al. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002 Oct; 54(4): 349–56PubMedCrossRefGoogle Scholar
  39. 39.
    Yue QY, Bergquist C, Gerden B. Safety of St John’s wort (Hypericum perforatum). Lancet 2000 Feb 12; 355(9203): 576–7PubMedCrossRefGoogle Scholar
  40. 40.
    Rey JM, Walter G. Hypericum perforatum (St John’s wort) in depression: pest or blessing? Med J Aust 1998 Dec 7-21; 169(11-12): 583–6PubMedGoogle Scholar
  41. 41.
    Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability [published erratum appears in Br J Clin Pharmacol 2002 Apr; 53 (4): 449P]. Br J Clin Pharmacol 2001 Nov; 52(5): 587–95PubMedCrossRefGoogle Scholar
  42. 42.
    Ladner DP, Klein SD, Steiner RA, et al. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. Br J Dermatol. 2001 Apr; 144(4): 916–8PubMedCrossRefGoogle Scholar
  43. 43.
    Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St John’s wort with cyclosporine [letter]. Lancet 2000 May 27; 355(9218): 1912PubMedCrossRefGoogle Scholar
  44. 44.
    Karliova M, Treichel U, Malago M, et al. Interaction of Hypericum perforatum (St John’s wort) with cyclosporine A metabolism in a patient after liver transplantation. J Hepatol 2000 Nov; 33(5): 853–5PubMedCrossRefGoogle Scholar
  45. 45.
    Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St John’s wort and cyclosporine. Ann Pharmacother 2000 Sep; 34(9): 1013–6PubMedCrossRefGoogle Scholar
  46. 46.
    Beckman SE, Sommi RW, Switzer J. Consumer use of St John’s wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000 May; 20(5): 568–74PubMedCrossRefGoogle Scholar
  47. 47.
    Lantz MS, Buchalter E, Giambanco V. St John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999 Spring; 12(1): 7–10PubMedCrossRefGoogle Scholar
  48. 48.
    Prost N, Tichadou L, Rodor F, et al. Interaction millepertuis-venlafaxine. Presse Med 2000 Jul 1; 29(23): 1285–6PubMedGoogle Scholar
  49. 49.
    Dannawi M. Possible serotonin syndrome after combination of buspirone and St John’s Wort [letter]. J Psychopharmacol 2002 Dec; 16(4): 401PubMedCrossRefGoogle Scholar
  50. 50.
    Gordon JB. SSRIs and St John’s Wort: possible toxicity? Am Fam Physician 1998 Mar 1; 57(5): 950–3PubMedGoogle Scholar
  51. 51.
    Barbenel DM, Yusufi B, O’Shea D, et al. Mania in a patient receiving testosterone replacement post-orchidectomy taking St John’ wort and sertraline. J Psychopharmacol 2000; 14(1): 84–6PubMedCrossRefGoogle Scholar
  52. 52.
    Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv 1999 Jul; 50(7): 969–70PubMedGoogle Scholar
  53. 53.
    Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St John’s wort. J Clin Anesth 2000 Sep; 12: 498–9PubMedCrossRefGoogle Scholar
  54. 54.
    Crowe S, McKeating K. Delayed emergence and St John’s wort. Anesthesiology 2002 Apr; 96(4): 1025–7PubMedCrossRefGoogle Scholar
  55. 55.
    Ahmed SM, Banner NR, Dubrey SW. Low cyclosporine-A level due to Saint-John’s-wort in heart transplant patients [letter]. J Heart Lung Transplant 2001 Jul; 20(7): 795795PubMedCrossRefGoogle Scholar
  56. 56.
    Alscher DM, Klotz U. Drug interaction of herbal tea containing St John’s wort with cyclosporine. Transpl Int. 2003 Jul; 16(7): 543–4PubMedCrossRefGoogle Scholar
  57. 57.
    Mandelbaum A, Pertzborn F, Martin-Facklam M, et al. Unexplained decrease of cyclosporine trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000; 15: 1473–4PubMedCrossRefGoogle Scholar
  58. 58.
    Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St John’s wort) after organ transplantation. Am J Kidney Dis 2001 Nov; 38(5): 1105–7PubMedCrossRefGoogle Scholar
  59. 59.
    Turton-Weeks SM, Barone GW, Gurley BJ, et al. St John’s wort: a hidden risk for transplant patients. Prog Transplant 2001 Jun; 11(2): 116–20PubMedGoogle Scholar
  60. 60.
    Beer AM, Ostermann T. St John’s wort: interaction with cyclosporine increases risk of rejection for the kidney transplant and raises daily cost of medication [in German]. Med Klin (Munich) 2001 Aug 15; 96(8): 480–3CrossRefGoogle Scholar
  61. 61.
    Breidenbach T, Kliem V, Burg M, et al. Profound drop of cyclosporine A whole blood trough levels caused by St John’s wort (Hypericum perforatum). Transplantation 2000 May 27; 69(10): 2229–30PubMedCrossRefGoogle Scholar
  62. 62.
    Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporine. Int J Clin Pharmacol Ther 2000 Oct; 38(10): 500–2PubMedGoogle Scholar
  63. 63.
    de Maat MM, Hoetelmans RM, Mathot RA, et al. Drug interaction between St John’s wort and nevirapine. AIDS 2001 Feb 16; 15(3): 420–1PubMedCrossRefGoogle Scholar
  64. 64.
    Ratz AE, von Moos M, Drewe J. St John’s wort: a pharmaceutical with potentially dangerous interactions [in German]. Schweiz Rundsch Med Prax 2001 May 10; 90(19): 843–9Google Scholar
  65. 65.
    Rossler MC, Wirthner D, Schnegg A, et al. Une grossesse sous Implanon®, la faute au millepertuis? Gynakol Geburtshilfliche Rundsch 2003; 43: 186–7Google Scholar
  66. 66.
    Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on selfmedication with St John’s wort despite hormonal contraception. Br J Clin Pharmacol 2003 Jan; 55(1): 112–3PubMedCrossRefGoogle Scholar
  67. 67.
    Vorsicht: “Pillen”-Versager durch Johanniskraut. Arznei-Telegramm 2001; 32 (3): 35Google Scholar
  68. 68.
    Eich-Hochli D, Oppliger R, Golay KP, et al. Methadone maintenance treatment and St John’s Wort: a case report. Pharmacopsychiatry 2003 Jan; 36(1): 35–7PubMedCrossRefGoogle Scholar
  69. 69.
    Bolley R, Zulke C, Kammerl M, et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s wort [letter]. Transplantation 2002 Mar 27; 73(6): 1009PubMedCrossRefGoogle Scholar
  70. 70.
    Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St John’s wort and theophylline. Ann Pharmacother 1999 Apr; 33(4): 502PubMedCrossRefGoogle Scholar
  71. 71.
    Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001 Dec; 70(6): 518–24PubMedCrossRefGoogle Scholar
  72. 72.
    Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporine A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients. Br J Clin Pharmacol 2003 Feb; 55(2): 203–11PubMedCrossRefGoogle Scholar
  73. 73.
    Mai I, Stormer E, Bauer S, et al. Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003 Apr; 18(4): 819–22PubMedCrossRefGoogle Scholar
  74. 74.
    Mathijssen RHJ, Verweij J, de Bruijn P, et al. Effects of St John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002 Aug 21; 94(16): 1247–9PubMedCrossRefGoogle Scholar
  75. 75.
    Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004 Feb; 75(2): P96CrossRefGoogle Scholar
  76. 76.
    Tannergren C, Engman H, Knutson L, et al. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004 Apr; 75(4): 298–309PubMedCrossRefGoogle Scholar
  77. 77.
    Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet 2000 Feb 12; 355(9203): 547–8PubMedCrossRefGoogle Scholar
  78. 78.
    Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St John’s wort (Hypericum perforatum). J Clin Psychopharmacol 2002 Feb; 22(1): 46–54PubMedCrossRefGoogle Scholar
  79. 79.
    Jiang X, Williams KM, Liauw WS, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004 May; 57(5): 592–9PubMedCrossRefGoogle Scholar
  80. 80.
    Maurer A, Johne A, Bauer S, et al. Interaction of St John’s wort extract with phenprocoumon [abstract]. Eur J Clin Pharmacol 1999; 55: A22Google Scholar
  81. 81.
    Kawaguchi A, Ohmori M, Tsuruoka S, et al. Effect of St John’s wort on the pharmacokinetics and pharmacodynamics of quazepam [abstract]. Clin Pharmacol Ther 2003 Feb; 73(2): 44CrossRefGoogle Scholar
  82. 82.
    Hall SD, Wang Z, Huang SM, et al. The interactions between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 2003 Dec; 74(6): 525–35PubMedCrossRefGoogle Scholar
  83. 83.
    Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003 Dec; 56(6): 683–90PubMedCrossRefGoogle Scholar
  84. 84.
    Brattström A. Der Johanniskrautextrakt ZE 117. Dtsch Apoth Ztg 2002 Jul 25; 142(30): 97–100Google Scholar
  85. 85.
    Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999 Oct; 66(4): 338–45PubMedCrossRefGoogle Scholar
  86. 86.
    Durr D, Stieger B, Kullak-Ublick GA, et al. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000 Dec; 68(6): 598–604PubMedCrossRefGoogle Scholar
  87. 87.
    Arold G, Donath F, Maurer A, et al. The influence of St John’s wort extract (St John’s wort, Esbericum capsules) on the pharmacokinetics of alprazolam, caffeine, tolbutamide and digoxin in man. In: 5th EACPT Congress; 2001; Odense. Pharmacol Toxicol 2001; 89Suppl. 1: 74–5Google Scholar
  88. 88.
    Mueller SC, Uehleke B, Woehling H, et al. Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004 Jun; 75(6): 546–57PubMedCrossRefGoogle Scholar
  89. 89.
    Wang LS, Zhou G, Zhu B, et al. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004 Mar; 75(3): 191–7PubMedCrossRefGoogle Scholar
  90. 90.
    Burstein AH, Horton RL, Dunn T, et al. Lack of effect of St John’s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000 Dec; 68(6): 605–12PubMedCrossRefGoogle Scholar
  91. 91.
    Wilkinson GR. Pharmacokinetics. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: MacGraw-Hill, 2001: 3–29Google Scholar
  92. 92.
    Rendic S, Di Carlo FJ. Human cytochrome P450 enzyme: a status report summarizing their reactions, substrates, induction, and inhibitors. Drug Metab Rev 1997; 29: 413–580PubMedCrossRefGoogle Scholar
  93. 93.
    Bodo A, Bakos E, Szeri F. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 2003 Apr 11; 140–141: 133-43Google Scholar
  94. 94.
    Roby CA, Anderson GD, Kantor E, et al. St John’s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000 May; 67(5): 451–7PubMedCrossRefGoogle Scholar
  95. 95.
    Wenk M, Todesco L, Krahenbuhl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004 Apr; 57(4): 495–9PubMedCrossRefGoogle Scholar
  96. 96.
    Bauer S, Stormer E, Kerb R, et al. Differential effects of St John’s wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6-p-hydroxycortisol in healthy volunteers. Eur J Clin Pharmacol 2002; 58: 581–5PubMedCrossRefGoogle Scholar
  97. 97.
    Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001 Oct; 70(4): 317–26PubMedGoogle Scholar
  98. 98.
    Dresser GK, Schwarz UI, Wilkinson GR, et al. St John’s wort induces intestinal and hepatic CYP3A4 and p-glycoprotein in healthy volunteers [abstract]. Clin Pharmacol Ther 2001 Feb; 69(2): 23Google Scholar
  99. 99.
    Xie R, Tan L, Polasek EC, et al. CYP3A and p-glycoprotein induction with St John’s wort in healthy volunteers of selected ethnic populations [abstract]. Clin Pharmacol Ther 2003 Feb; 73(2): 93CrossRefGoogle Scholar
  100. 100.
    Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002 Sep; 72(3): 276–87PubMedCrossRefGoogle Scholar
  101. 101.
    Smith M, Lin KM, Zheng YP. An open trial of nifedipine-herb interactions: nifedipine with St John’s wort, ginseng or Ginkgo biloba [abstract]. Clin Pharmacol Ther 2001 Feb; 69(2): P86Google Scholar
  102. 102.
    Ereshefsky B, Gewertz N, Lam YWF, et al. Determination of St John’s wort differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology [poster no. 130]. 39th Annual NCDEU Meeting; 1999 Jun 3, Boca Raton (FL)Google Scholar
  103. 103.
    Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000 Jan 21; 66(9): PL133–9PubMedCrossRefGoogle Scholar
  104. 104.
    Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003 Sep 17; 290(11): 1500–4PubMedCrossRefGoogle Scholar
  105. 105.
    Roby CA, Dryer DA, Burstein AH. St John’s wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001 Oct; 21(5): 530–2PubMedCrossRefGoogle Scholar
  106. 106.
    Gewertz N, Ereshefsky B, Lam YWF, et al. Determination of the differential effects of St John’s wort on the CYP1A2 and NAT2 metabolic pathways using caffeine probe methodology [poster no. 131]. 39th Annual NCDEU Meeting; 1999 Jun 3, Boca Raton (FL)Google Scholar
  107. 107.
    Chang M, Tybring G, Dahl ML, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995 May; 39(5): 511–8PubMedCrossRefGoogle Scholar
  108. 108.
    Kaminsky LS, de Morais SM, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993 Feb; 43(2): 234–9PubMedGoogle Scholar
  109. 109.
    Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline Ndemethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998 Feb; 38(2): 112–21PubMedGoogle Scholar
  110. 110.
    Hamman MA, Wang Z, Honig P, et al. Effects of acute and chronic St John’s wort (St John’s wort ) administration on fexofenadine (FEX) disposition [abstract]. Clin Pharmacol Ther 2001 Feb; 69(2): 53Google Scholar
  111. 111.
    Wang Z, Hamman MA, Huang SM, et al. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002 Jun; 71(6): 414–20PubMedCrossRefGoogle Scholar
  112. 112.
    Schwarz UI, Hanso H, Dreser GK, et al. St John’s wort reduces oral bioavailability of talinolol in healthy volunteers [abstract]. Clin Pharmacol Ther 2002 Feb; 71(2): 33Google Scholar
  113. 113.
    Drewe J, Gutmann H, Toeroek M, et al. Mechanismen der Interaktionen mit Johanniskrautextrakten. In: Rietbrock N, editor. Phytopharmaka VI: Forschung und klinische Anwendung. Darmstadt: Steinkopff, 2000: 75–81Google Scholar
  114. 114.
    Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002 Jan; 53(1): 75–82PubMedCrossRefGoogle Scholar
  115. 115.
    Hehl EM, Muller S, Wutzke KD, et al. Influence of St John’s wort on oro-coecal transit time in healthy volunteers [abstract]. From the 5th EACPT Congress; 2001, Odense. Pharmacol Toxicol 2001; 89Suppl. 1: 76Google Scholar
  116. 116.
    Bray BJ, Perry NB, Menkes DB, et al. St John’s wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 2002 Mar; 66(1): 27–33PubMedCrossRefGoogle Scholar
  117. 117.
    Cantoni L, Rozio M, Mangolini A, et al. Hyperforin contributes to the Hepatic CYP3A-inducing effect of hypericum perforatum extract in the mouse. Toxicol Sci 2003 Sep; 75: 25–30PubMedCrossRefGoogle Scholar
  118. 118.
    Bray BJ, Brennan NJ, Perry NB, et al. Short term treatment with St John’s wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse. Life Sci 2002 Feb 1; 70(11): 1325–35PubMedCrossRefGoogle Scholar
  119. 119.
    Noeldner M, Chatterjee S. Effects of two different extracts of St John’s wort and some of their constituents on cytochrome P450 activities in rat liver microsomes. Pharmacopsychiatry 2001 Jul; 34Suppl. 1: S108–10CrossRefGoogle Scholar
  120. 120.
    Gerloff T, Störmer E, Mrozikiewicz PM, et al. Hypericum perforatum (St John’s wort) has no effect on protein expression of intestinal p-glycoprotein (MDR1) in the rat. Presented at the Joint Meeting of the VII. World Conference on Clinical Pharmacology and Therapeutics and 4th Congress of the European Association of Clinical Pharmacology and Therapuetics; 2000 Jul 15-20; Florence: 194Google Scholar
  121. 121.
    Dürr D, Stieger B, Meier PJ, et al. St John’s wort (St John’s wort) and dexamethasone (DEX) selectively induce hepatic Oatp2 expression in rats. In: 5th European Association for Clinical Pharmacology and Therapeutics Congress; 2001; Odense. Pharmacol Toxicol 2001; 89Suppl. 1: 73Google Scholar
  122. 122.
    Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000 Jul; 294(1): 88–95PubMedGoogle Scholar
  123. 123.
    Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000 Jul; 7(4): 273–82PubMedCrossRefGoogle Scholar
  124. 124.
    Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic acitivity. Life Sci 2002 Aug 16; 71(13): 1579–89PubMedCrossRefGoogle Scholar
  125. 125.
    Schwarz D, Kisselev P, Roots I. St John’s wort extracts and some of their constituents potently inhibit ultimate carcinogen 795 formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. Cancer Res 2003 Nov 15; 63(22): 8062–8PubMedGoogle Scholar
  126. 126.
    Perloff MD, Stormer E, von Moltke LL, et al. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003 Aug; 20(8): 1177–83PubMedCrossRefGoogle Scholar
  127. 127.
    Carson SW, Hill-Zabala CE, Blalock SB, et al. Constituents of St John’s wort inhibit cytochrome P450 3A4 and P450 reductase activity in human liver microsomes [abstract]. Clin Pharmacol Ther 2000 Feb; 67(2): 99Google Scholar
  128. 128.
    Carson SW, Hill-Zabala CE, Roberts SH, et al. Inhibitory effect of methanolic solution of St John’s wort (Hypericum perforatum) on cytochrome P450 3A4 activity in human liver microsomes [abstract]. Clin Pharmacol Ther 2001 Feb; 69(2): 8Google Scholar
  129. 129.
    Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002 Jun; 32(6): 451–78PubMedCrossRefGoogle Scholar
  130. 130.
    Krusekopf S, Roots I, Kleeberg U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol 2003 Apr 11; 466(1-2): 7–12PubMedCrossRefGoogle Scholar
  131. 131.
    Moore LB, Goodwin B, Jones SA, et al. St John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000 Jun 20; 97(13): 7500–2PubMedCrossRefGoogle Scholar
  132. 132.
    Karyekar CS, Eddington ND, Dowling TC. Effect of St John’s Wort extract on intestinal expression of cytochrome P4501A2: studies in LS180 cells. J Postgrad Med 2002 Apr-Jun; 48(2): 97–100PubMedGoogle Scholar
  133. 133.
    Peebles KA, Baker RK, Kurz EU, et al. Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St John’s wort (Hypericum perforatum). Biochem Pharmacol 2001 Oct 15; 62(8): 1059–70PubMedCrossRefGoogle Scholar
  134. 134.
    Watkins RE, Maglich JM, Moore LB, et al. A crystal structure of human PXR in complex with the St John’s wort compound hyperforin. Biochemistry 2003 Feb 18; 42(6): 1430–8PubMedCrossRefGoogle Scholar
  135. 135.
    Perloff MD, von Moltke LL, Stormer E, et al. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001 Dec; 134(8): 1601–8PubMedCrossRefGoogle Scholar
  136. 136.
    Troutman MD, Thakker DR, Carson SW, et al. Activation and inhibition of P-glycoprotein (P-gp) mediated efflux of digoxin by St John’s wort extract [abstract]. AAPS Pharm Sci 2000; 4: 948. Available from URL: http://www.aapspharmsci.org/ [Accessed 2003 Jul 20]Google Scholar
  137. 137.
    Sonoda J, Rosenfeld JM, Xu L, et al. A nuclear receptormediated xenobiotic response and its implication in drug metabolism and host protection. Curr Drug Metab 2003 Feb; 4(1): 59–72PubMedCrossRefGoogle Scholar
  138. 138.
    Kerb R, Brockmoller J, Staffeldt B, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40: 2087–93PubMedGoogle Scholar
  139. 139.
    Biber A, Fischer H, Romer A, et al. Oral bioavailability of hyperforin extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31: 36–43PubMedCrossRefGoogle Scholar
  140. 140.
    Wentworth JM, Agostini M, Love J, et al. St John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000 Sep; 166(3): R11–6PubMedCrossRefGoogle Scholar
  141. 141.
    Chen Y, Ferguson SS, Negishi M, et al. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor (PXR). J Pharmacol Exp Ther 2004 Feb; 308(2): 495–501PubMedCrossRefGoogle Scholar
  142. 142.
    Parker V, Wong AH, Boon HS, et al. Adverse reactions to St John’s Wort. Can J Psychiatry 2001 Feb; 46(1): 77–9PubMedGoogle Scholar
  143. 143.
    Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: MacGraw-Hill, 2001: 278–81Google Scholar
  144. 144.
    Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999 Mar; 16(3): 408–14PubMedCrossRefGoogle Scholar
  145. 145.
    Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993 Oct; 79(4): 795–807PubMedCrossRefGoogle Scholar
  146. 146.
    Thummel KE, Kharasch ED, Podoll T, et al. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 1993 Mar-Apr; 21(2): 350–7PubMedGoogle Scholar
  147. 147.
    Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther 1989; 45(5): 476–86PubMedCrossRefGoogle Scholar
  148. 148.
    Morimoto T, Kotegawa T, Tsutsumi K, et al. Effect of St John’s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004; 44(1): 95–101PubMedCrossRefGoogle Scholar
  149. 149.
    Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P450. Br J Clin Pharmacol 1995; 39: 321–6PubMedCrossRefGoogle Scholar
  150. 150.
    Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002 Oct; 23(5): 687–702PubMedCrossRefGoogle Scholar
  151. 151.
    Xie W, Evans RM. Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 2001 Oct 12; 276(41): 37739–42PubMedGoogle Scholar
  152. 152.
    Melzer M, Fuhrken D, Kolkmann R. Hyperforin im Johanniskraut. Dtsch Apoth Ztg 1998; 138: 4754–60Google Scholar
  153. 153.
    Conseil G, Baubichon-Cortay H, Dayan G, et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci U S A 1998 Aug 18; 95(17): 9831–6PubMedCrossRefGoogle Scholar
  154. 154.
    Leslie EM, Mao Q, Oleschuk CJ, et al. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol 2001 May; 59(5): 1171–80PubMedGoogle Scholar
  155. 155.
    Zhou S, Gao Y, Jiang W, et al.1171-80 Interactions of herbs with cytochrome P450. Drug Metab Rev 2003 Feb; 35(1): 35–98PubMedCrossRefGoogle Scholar
  156. 156.
    Meier B. Comparing phytopharmaceuticals: the example of St John’s wort. Adv Ther 2001 Jan-Feb; 18(1): 35–46PubMedCrossRefGoogle Scholar
  157. 157.
    Chatterjee SS, Noldner M, Koch E, et al. Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 1998 Jun; 31Suppl. 1: 7–15PubMedCrossRefGoogle Scholar
  158. 158.
    Groning R, Breitkreutz J, Muller RS. Physico-chemical interactions between extracts of Hypericum perforatum L. and drugs. Eur J Pharm Biopharm 2003 Sep; 56(2): 231–6PubMedCrossRefGoogle Scholar
  159. 159.
    Wang EJ, Barecki-Roach M, Johnson WW. Quantitative characterization of direct P-glycoprotein inhibition by St John’s wort constituents hypericin and hyperforin. J Pharm Pharmacol 2004 Jan; 56(1): 123–8PubMedCrossRefGoogle Scholar
  160. 160.
    Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes p450 by the St John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004 May; 32(5): 512–8PubMedCrossRefGoogle Scholar
  161. 161.
    Heinemeyer G, Roots I, Lestau P, et al. D-glucaric acid excretion in critical care patients -comparison with 6-beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy. Br J Clin Pharmacol 1986 Jan; 21(1): 9–18PubMedCrossRefGoogle Scholar
  162. 162.
    Roots I, Holbe R, Hovermann W, et al. Quantitative determination by HPLC of urinary 6beta-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol 1979 Aug; 16(1): 63–71PubMedCrossRefGoogle Scholar
  163. 163.
    Hildebrandt AG, Roots I, Speck M, et al. Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo. Eur J Clin Pharmacol 1975 Jun 13; 8(5): 327–36PubMedCrossRefGoogle Scholar
  164. 164.
    Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984 Sep; 18(3): 401–10PubMedCrossRefGoogle Scholar
  165. 165.
    Ohnhaus EE, Kirchhof B, Peheim E. Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin. Clin Pharmacol Ther 1979 May; 25(5 Pt 1): 591–7PubMedGoogle Scholar
  166. 166.
    Perucca E, Richens A. Reversal by phenytoin of carbamazepineinduced water intoxication: a pharmacokinetic interaction. J Neurol Neurosurg Psychiatry 1980 Jun; 43(6): 540–5PubMedCrossRefGoogle Scholar
  167. 167.
    Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973; 49(4): 543–6PubMedCrossRefGoogle Scholar
  168. 168.
    Franklin M, Reed A, Murck H. Sub-chronic treatment with an extract of Hypericum perforatum (St John’s wort) significantly reduces cortisol and corticosterone in the rat brain. Eur Neuropsychopharmacol 2004 Jan; 14(1): 7–10PubMedCrossRefGoogle Scholar
  169. 169.
    Lam FC, Liu R, Lu P, et al. Beta-Amyloid efflux mediated by pglycoprotein. J Neurochem 2001 Feb; 76(4): 1121–8PubMedCrossRefGoogle Scholar
  170. 170.
    Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002 Oct; 12(7): 535–41PubMedCrossRefGoogle Scholar
  171. 171.
    Xie W, Radominska-Pandya A, Shi Y, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 2001 Mar 13; 98(6): 3375–80PubMedCrossRefGoogle Scholar
  172. 172.
    Tabb MM, Sun A, Zhou C, et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor, SXR. J Biol Chem 2003 Nov 7; 278(45): 43919–27PubMedCrossRefGoogle Scholar
  173. 173.
    Walter G, Rey JM, Harding A. Psychiatrists’ experience and views regarding St John’s wort and “alternative” treatments. Aust N Z J Psychiatry 2000 Dec; 34(6): 992–6PubMedCrossRefGoogle Scholar
  174. 174.
    Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001 Jul 11; 286(2): 208–16PubMedCrossRefGoogle Scholar
  175. 175.
    Hodges PJ, Kam PC. The peri-operative implications of herbal medicines. Anaesthesia 2002 Sep; 57(9): 889–99PubMedCrossRefGoogle Scholar
  176. 176.
    Skinner CM, Rangasami J. Preoperative use of herbal medicines: a patient survey. Br J Anaesth 2002 Nov; 89(5): 792–5PubMedCrossRefGoogle Scholar
  177. 177.
    de Maat MM, Ekhart GC, Huitema AD, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42(3): 223–82PubMedCrossRefGoogle Scholar
  178. 178.
    Chabner BA, Ryan DP, Paz-Ares L, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: MacGraw-Hill, 2001: 1389–1459Google Scholar
  179. 179.
    Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003 Jul; 2(7): 404–9PubMedCrossRefGoogle Scholar
  180. 180.
    Majerus PW, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: MacGraw-Hill, 2001: 1519–38Google Scholar
  181. 181.
    Shader RI, Oesterheld JR. Contraceptive effectiveness: cytochromes and induction. J Clin Psychopharmacol 2000 Apr; 20(2): 119–21PubMedCrossRefGoogle Scholar
  182. 182.
    Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988 May; 33(5): 500–8PubMedGoogle Scholar
  183. 183.
    Bolt HM, Bolt M, Kappus H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol (Copenh) 1977 May; 85(1): 189–97Google Scholar
  184. 184.
    Murphy PA. St John’s wort and oral contraceptives: reasons for concern? J Midwifery Womens Health 2002 Nov-Dec; 47(6): 447–50PubMedCrossRefGoogle Scholar
  185. 185.
    Murphy PA. Examination of the effect of St John’s Wort on contraceptive efficacy [oral presentation]. Presented at the 40th Annual Meeting, Association of Reproductive Health Professionals; 2003 Sep 11, La Jolla (CA)Google Scholar
  186. 186.
    Irish Medicines Board (IMB). Drug safety newsletter. 9th ed. no. 10. Dublin: IMB, 2000: 3Google Scholar
  187. 187.
    Swissmedic. Interaktionspotential von Spezialitaten mit Hypericum perforatum. Abschluss des Gruppenrevisionsverfahrens [Interaction potential of drug preparations containing Hypericum perforatum. Completion of the safety risk clearance procedure]. Swissmedic J 2002; 1: 7Google Scholar
  188. 188.
    Swissmedic. Interaktionspotenzial von Arzneimitteln mit Hypericum perforatum — Verfügung bezüglich der MRAuflagen im Rahmen des Überprufungsverfahrens nach Art. [Mandate concerning monitored-release imposts regarding the interaction potential of drug preparations containing Hypericum perforatum. Registered letter to St John’s wort drug manufacturers. 16 Abs. 2 des Heilmittelgesetzes (HMG) und Art. 58 Abs. 3 HMG]. Swissmedic 2003 Sep 19Google Scholar
  189. 189.
    Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 2002 Jun; 8(3): 293–308PubMedCrossRefGoogle Scholar
  190. 190.
    Deferme S, Augustijns P. The effect of food components on the absorption of P-gp substrates: a review. J Pharm Pharmacol 2003 Feb; 55(2): 153–62PubMedCrossRefGoogle Scholar
  191. 191.
    Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. Ann Pharmacother 2002 Dec; 36(12): 1893–6PubMedCrossRefGoogle Scholar
  192. 192.
    Koumaravelou K, Adithan C, Shashindran CH, et al. Effect of honey on carbamazepine kinetics in rabbits. Indian J Exp Biol 2002 May; 40(5): 560–3PubMedGoogle Scholar
  193. 193.
    Koumaravelou K, Adithan C, Shashindran CH, et al. Influence of honey on orally and intravenously administered diltiazem kinetics in rabbits. Indian J Exp Biol 2002 Oct; 40(10): 1164–8PubMedGoogle Scholar
  194. 194.
    Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001 Nov; 70(5): 462–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Ad libitum Medical ServicesBerlinGermany

Personalised recommendations